Torrent Pharmaceuticals Hits Record High After Strong Q4 Revenue Growth

$TORNTPHARM reported a mixed Q4 performance on a consolidated YoY basis. Net profit declined 21.9% to Rs 389 crore compared to Rs 498 crore in the corresponding quarter last year. However, revenue surged 41.8% to Rs 4,197 crore against Rs 2,959 crore, reflecting strong business growth and robust demand momentum. Despite the profit decline, investor sentiment remained highly positive as the stock touched a fresh all-time high of Rs 4,712.9 on 25 May 2026 during trade, indicating confidence in the company’s long-term growth outlook and operational strength. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes only. Investors must verify information before investing and consider their financial position & risk profile.